Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Pharmaceutical Business ReviewThe application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility.RegulatoryOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Business Review The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly doubles down on in vivo with $7bn Kelonia buyoutNext: FDA kicks off review of Roche’s Gazyva for wider lupus use Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
